CONTEXT:Several studies have reported that thrombophilia is responsible for recurrent pregnancy loss (RPL).AIMS:The aim of this study was to evaluate the prevalence and role of inherited thrombophilia in early pregnancy loss, specifically in the first trimester.MATERIALS AND METHODS:A total of 104 women (patients) with a history of two or more miscarriages during the first trimester of pregnancy and 110 women (controls) who had experienced two or more births without a miscarriage were included in this study. In both groups, we determined the biological activities of antithrombin III (ATIII) and protein C (PC) using the chromogenic method and the biological activity of protein S (PS) and the activated protein C resistance (APCR) were examined using a clotting method.RESULTS:In the patient group, deficiencies of ATIII, PC, and PS were detected in 3 (2.88%), 4 (3.85%), and 6 (5.77%) cases, respectively. In the control group, ATIII (0%) deficiencies were not detected, and deficiencies for PC (0.9%) and PS (0.9%) were each detected in 1 patient. APCR was detected in 9 patients (8.65%) and 4 control subjects (3.63%).CONCLUSION:Based on our results, we can conclude that thrombophilia is a causal factor for miscarriages in the first trimester of pregnancy, although there are the conflicting data in the literature.
Introduction: Preeclampsia is a disease whose etiology is not very clearly explained. The aim of this study was to investigate the importance of blood urea nitrogen (BUN)/creatinine ratio in diagnosing preeclampsiaand evaluating prognosis.Methods: The patients in this research were examined and diagnosed in the Department of Obstetrics and Gynecology, University Clinical Centre of Kosovo. Control group included 25 pregnant women with a normalblood pressure and with a gestational age of more than 20 weeks, whereas the investigation group included 25 women diagnosed with preeclampsia. The patients were not administered therapy four days before the examination. For the determination of biochemical parameters we used end point bichromatic enzymatic rate and enzymatic conductivity rate.Results: BUN/Creatinine index in the preeclamptic group was 19±7.7, uric acid 280±70 μmol/L, lactate dehydrogenase198±63 U/L, while the number of platelets was 195±5061 x 109/L. In control group BUN/Creatinine index was 12±3, lactate dehydrogenase was 165±57 U/L, uric acid 197±79 μmol/La and the platelet numberwas 243±61 x109/L. Albumin/Globulin index in the preeclamptic group was 0.8±0.12, whereas in the control group it was 0.9±0.16.Conclusions: BUN/Creatinine ratio in pregnant women with preeclampsia was significantly increased (t=-4.14; p=0.00013) in comparison to the control group. It indicates the prerenal source of azotemia. This indexcan be important for the evaluation of preeclampsia severity.
Introduction:As in most countries of the world also at Kosovo the rate of Cesarean section from year to year is increasing.Aim:The main purpose of this paper was to present the incidence of births completed by Caesarean section at the Clinic of Gynecology and Obstetrics of University Clinical Center of Kosovo in Prishtinë.Material and methods:This study is retrospective, namely its made by collecting epidemiological data from patients’ histories that completed birth by Caesarean section for the period 2000-2006 in this clinic.Results and discussion:During this period, 14 maternal deaths were recorded during or after Caesarean section. Besides this, 14 lethal outcomes, the object of our study was 84 mothers which completed birth by Caesarean section and which are best used as a control group. The average age of mothers who died during or after Caesarean section was 32.1 years (SD ± 4.9). Youngest in this group was 24 years old and oldest 42 years. While the average age of mothers from the control group was 30.6 years (SD ± 5.9). Youngest was 19 and oldest 43 years, without significant difference. Most mothers included in the survey had more than one indication for Caesarean section. The most frequent indication was PIH syndrome with 33.7% and previous Caesarean section in 32.7%. Then with the participation of 12.2% were abruption of the placenta and disproportio feto pelvinea, 11.2% pelvinea and placenta praevia presentation, 10.2% parturiens while other indications were much rarer with less than 10% participation.Conclusion:Based on this we can conclude that the risk of the Caesarean section is high.
IntroductionAcute leukemia is rare in pregnancy. The importance of promptly diagnosing and treating this disease in pregnancy stems from its life-threatening potential, both to the mother and fetus.Case presentationWe report a case of relapse of acute myeloid leukemia at 23 weeks of pregnancy in a 24-year-old Albanian woman. Our patient categorically refused chemotherapy treatment, and in her 35th week of gestation, severe hemorrhagic diathesis rapidly developed. The manifestation and course of this life-threatening complication posed therapeutic challenges for the attending medical team.ConclusionBased both on our experience and the results of other gynecological studies, there exists a strong indication that the earlier a patient’s chemotherapy treatment begins, the better the maternal outcome. We support chemotherapy for patients who are pregnant presenting with such illness. The present case report testifies that refusal of chemotherapy by such patients is a high-risk decision.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.